Kiniksa Pharmaceuticals News

Express News | Kiniksa Pharmaceuticals - Expects Redomiciliation To Take Effect On Or Around June 27, 2024; Supreme Court Of Bermuda Issued An Order Sanctioning Scheme Of Arrangement Between Company And Its Shareholders

BenzingaJun 14 16:32 ET

Express News | Kiniksa Pharmaceuticals Ltd - Supreme Court of Bermuda Issued an Order Sanctioning Scheme of Arrangement Between Company and Its Shareholders

ReutersJun 14 16:29 ET

Express News | Kiniksa Pharmaceuticals Ltd - Expects Redomiciliation to Take Effect on or Around June 27, 2024

ReutersJun 14 16:29 ET

Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

PDF Version HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman

Kiniksa PharmaceuticalsJun 4 00:00 ET

Sector Spotlight: Orphan Drug Developers With Significant Upside

Stockhouse Jun 3 07:00 ET

Market Underestimates Kiniksa Pharmaceuticals' Abiprubart Potential Despite Positive Industry Indicators

TipRanksMay 10 06:03 ET

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

PDF Version HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of A

Kiniksa PharmaceuticalsMay 7 00:00 ET

Express News | Wells Fargo Initiates Coverage On Kiniksa Pharmaceuticals With Overweight Rating, Announces Price Target of $34

BenzingaMay 3 11:48 ET

Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan

Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow JonesMay 1 10:58 ET

Express News | JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $30

BenzingaMay 1 10:47 ET

Express News | Kiniksa Pharmaceuticals Ltd : JP Morgan Raises Target Price to $30 From $26

ReutersApr 30 23:43 ET

Kiniksa Pharmaceuticals (NASDAQ:KNSA): New Drug Treatment Could Have Upside Potential

TipRanksApr 30 03:40 ET

Kiniksa Pharmaceuticals Faces Capital Raising Hurdles Amid Stricter UK Shareholder Voting Laws

TipRanksApr 27 02:00 ET

Analyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter Report

Yahoo FinanceApr 26 06:37 ET

Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group

Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group

Dow JonesApr 24 13:50 ET

Kiniksa Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 63.49% Evercore ISI Group $25 → $30 Maintains Outperform 01/02/2024 36.24% Wedbush $23 → $25 Ma

BenzingaApr 24 13:38 ET

Express News | Kiniksa Pharmaceuticals Ltd : Evercore ISI Raises Target Price to $30 From $25

Moomoo 24/7Apr 24 09:18 ET

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript

Yahoo FinanceApr 24 09:00 ET

Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects

TipRanksApr 24 05:44 ET

Earnings Call Summary | Kiniksa Pharmaceuticals(KNSA.US) Q1 2024 Earnings Conference

The following is a summary of the Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcript:Financial Performance:Kiniksa Pharmaceuticals reported strong Q1 2024 results with an 85% year-ov

moomoo AIApr 23 16:12 ET · Conference Call